Thursday, January 21, 2010

Indian pharma starts 2010 with infringement lawsuits in the United States

Indian pharma companies started New Year with at least two patent infringement lawsuits filed against them in the United States. First case was filed on 6th day of the year 2010 by Teva Women’s Health (Duramed) against Pune-based generic manufacturer Lupin Limited (Teva Women’s Health, Inc. v. Lupin Ltd. et al., District Court of New Jersey, Case # 2:2010cv00080). The case was filed in the District Court of New Jersey for infringement of US Pat. No. 7,615,545 lately listed with the Orange Book for newly approved ethinylestradiol and levonorgestrel combination oral contraceptive drug LoSeasonique.

Second case was filed on January 13 by Takeda Pharmaceutical against Hyderabad-based generic manufacturer Aurobindo Pharma Limited (Takeda Pharmaceutical Company Limited et al v. Aurobindo Pharma Limited, New York Southern District Court, Case # 1:2010cv00247). However, we are not sure about the drug product for which patent infringement suit is filed. Readers any information on this.

5 comments:

  1. Anonymous11:52 AM

    VC,

    Pls do not undermine yourself by reporting such infringement updates. You have risen above this all.
    Pls post more insightful and thought provoking analysis... that would minds into work. we all know you are capable of doing this.

    Just a friendly advise. Don't take otherwise!

    AKG

    ReplyDelete
  2. These patent infringements are no great feat i believe given that loseasonique is small and pioglitazone already has many filers.

    Would rather feel happy with better and larger filings by Indian companies.

    Just a thought...

    ReplyDelete
  3. Anonymous10:09 PM

    Hi Girish,
    r u sure the second case is related to pioglitazone?

    ReplyDelete
  4. Anonymous12:43 AM

    Pretty interesting blog you've got here. Thanx for it. I like such topics and anything connected to this matter. I definitely want to read more soon.

    ReplyDelete
  5. Yes Aurobindo Takeda case is for pioglitazone.

    Affirmative!

    ReplyDelete